A 2-Cohort Study to Evaluate the Absolute Bioavailability, Absorption, Distribution, Metabolism and Excretion of TD-1473 Following an Intravenous and an Oral Dose of [14C]-TD-1473 in Healthy Male Subjects

Next Previous
Trial Profile

A 2-Cohort Study to Evaluate the Absolute Bioavailability, Absorption, Distribution, Metabolism and Excretion of TD-1473 Following an Intravenous and an Oral Dose of [14C]-TD-1473 in Healthy Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Apr 2018

At a glance

  • Drugs TD 1473 (Primary) ; TD 1473 (Primary)
  • Indications Gastrointestinal disorders; Inflammatory bowel diseases; Ulcerative colitis
  • Focus Pharmacokinetics
  • Sponsors Theravance Biopharma

    • Most Recent Events

    • 13 Apr 2018 Status changed from recruiting to completed.
    • 30 Jan 2018 Planned initiation date changed to 31 Jan 2018.
    • 29 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top